Pace Life Sciences LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace, has announced significant growth plans for two of its locations.

The company’s facility expansions in Salem, NH, and Oakdale, MN, will increase sterile fill-finish capacity and improve analytical capabilities to better assist clients working on biologics, gene therapies, and other innovative molecules.

“Building upon these sites gives us the ability to accelerate clinical trial materials development for our clients and underserved markets,” stated Frank Tagliaferri, Chief Science Officer, for Pace Life Sciences.

The Oakdale Campus

The Oakdale campus was awarded a grant from the Minnesota Department of Employment and Economic Development (DEED) in 2024 to help fund its expansion. The site will remain fully operational during construction adding 8,000 square feet for testing drugs reaching the commercial phase of production and is expected to create more than 50 new jobs. The expansion includes a dedicated RNase-free environment and extensive cell-based assay support.

The Salem Facility

Upon completion, the Salem, NH facility will be classified as a Center of Excellence (CoE) for Sterile Fill-Finish processing.

“The addition of our isolated vial filling line as part of the Salem expansion gives us a state-of-the-art capability for manufacturing clinical supplies with the highest level of sterility assurance and EU Annex 1 compliance,” explained Tagliaferri. “This fill line and other facility enhancements enable us to provide industry leading service to our clients requiring cGMP manufacturing in the injectable space for vaccines, gene therapies, antibodies, and protein-based therapeutics.”

“In 2024, we completed our largest acquisition to date with the addition of our Research Triangle Park, NC, location and gained expertise in Container Closure Integrity Testing (CCIT) with our Lebanon, NJ, acquisition,” noted Dawn Von Rohr, President of Pace Life Sciences. “This year, we remain committed to seeking additional key opportunities to increase capabilities and expand our capacity to support our greater mission of improving patient lives.”